News

TransAlta Announces Right to Convert Series G Preferred Shares

TransAlta Announces Right to Convert Series G Preferred Shares

Update on TransAlta's Series G Preferred Shares

TransAlta Corporation (TSX: TA; NYSE: TAC) has shared important news about its cumulative redeemable rate reset first preferred shares, known as Series G. The company has decided not to exercise its right to redeem these shares on the upcoming conversion date.

Details on the Conversion of Series G Shares

Holders of Series G Shares will have the chance to convert their shares into cumulative redeemable floating rate first preferred shares, referred to as Series H Shares. This conversion will follow the established ratio, allowing shareholders to receive one Series H Share for each Series G Share they own, subject to certain terms and conditions.

Upcoming Dividend Rate Announcements

The company will announce the upcoming dividend rate for Series G Shares for the period from September 30, 2024, to September 30, 2029, as well as the rate for Series H Shares for the three-month period starting September 30, 2024. This information will be shared through a news release on September 3, 2024.

Conditions Affecting Conversion

TransAlta has specified conditions that could influence the conversion process. If there are fewer than 1,000,000 Series G Shares outstanding on the conversion date, all Series G Shares will automatically convert to Series H Shares. On the other hand, if there are fewer than 1,000,000 Series H Shares available after the conversion, shareholders will not be able to convert their Series G Shares into Series H Shares.

Important Information on the Process and Deadlines

Shareholders who wish to convert their shares should remember that they must submit their exercise notification before the deadline of September 16, 2024, by 3:00 p.m. (MST) / 5:00 p.m. (EST). This conversion process must be done through a CDS Participant, and it is essential for shareholders to ensure their requests are submitted on time to avoid missing the deadline.

Approval from the Stock Exchange

The Toronto Stock Exchange (TSX) has granted conditional approval for the listing of Series H Shares, which will take effect upon conversion. This step is designed to enhance shareholder engagement and ensure compliance with listing requirements.

About TransAlta Corporation

TransAlta is a prominent energy provider with a diverse portfolio of power generation assets across various markets, including wind and hydroelectric power. The company is dedicated to sustainable energy solutions and aims to provide long-term value to its shareholders. With over a century of experience, TransAlta is committed to environmentally responsible practices and aligns its goals with internationally recognized sustainable development objectives.

Commitment to Sustainability

The company has made significant strides in reducing greenhouse gas (GHG) emissions, achieving a notable decrease since 2015. TransAlta's alignment with the UN Sustainable Development Goals underscores its commitment to corporate responsibility and environmental stewardship.

Contact Information for the Company

For investor inquiries, please call 1-800-387-3598 in Canada and the US, or email investor_relations@transalta.com. For media inquiries, contact 1-855-255-9184 or email ta_media_relations@transalta.com.

Frequently Asked Questions

What are the Series G Shares of TransAlta?

Series G Shares are cumulative redeemable rate reset first preferred shares issued by TransAlta, which grant holders specific rights to convert into Series H Shares.

When will the conversion of Series G Shares take place?

The conversion right is scheduled for September 30, 2024, with the notice period closing on September 16, 2024.

What happens if I miss the conversion deadline?

If the election notice is not submitted on time, the Series G Shares will remain unchanged and will not convert, unless an automatic conversion occurs.

How can I learn more about TransAlta?

For more information, you can visit transalta.com, where you will find comprehensive details about their operations and sustainability initiatives.

What is TransAlta's approach to sustainability?

TransAlta is dedicated to sustainable practices and has achieved significant reductions in GHG emissions, aligning its objectives with the UN Sustainable Development Goals.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 80

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 242

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 559

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 74

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 25

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 343

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Alert: LifeMD Inc Faces Legal Investigation Risks

Updated Category News Views 167

Understanding Recent Developments for LifeMD, Inc. LifeMD, Inc. (NASDAQ: LFMD) is presently facing serious legal scrutiny following an investigation initiated by Faruqi & Faruqi, LLP. This renowned national securities law firm has stepped in to evaluate potential claims on behalf of investors. Investor Engagement Opportunities If you are among the investors who incurred...

Continue Reading
Value Stocks Poised for Growth Amid Market Shifts

Updated Category News Views 119

Value Stocks Set for Growth as Market Dynamics Change The stock market is currently experiencing a notable shift away from tech dominance. In recent months, tech stocks have faced challenges, raising questions about the potential revival of value stocks. This change in market sentiment is particularly evident in the impressive performance of the Value ETF, which has...

Continue Reading
EXEL Industries Reveals Key Share and Voting Rights Insights

Updated Category News Views 57

EXEL Industries Overview EXEL Industries is a prominent French Société Anonyme, with a robust share capital amounting to €16,969,750. The company has established a significant presence in the industry through its high standards and innovative products. Understanding Share Capital and Voting Rights On August 31, 2024, EXEL Industries provided updated insights regarding...

Continue Reading
Protective Life Corporation Strengthens Portfolio with Acquisition

Updated Category News Views 112

Protective Life Corporation Strengthens Its Portfolio In a significant development for Protective Life Corporation, the company has successfully completed the acquisition of ShelterPoint Group, Inc. Shielded under the corporate umbrella of Dai-ichi Life Holdings, Inc., Protective Life Corporation continues to solidify its position in the employee benefits industry. This...

Continue Reading
Safeguarding Your Personal Data in a Digital Health Era

Updated Category News Views 160

Understanding the Importance of Data Security in Health Tech As the holiday season approaches, consumers are excitedly purchasing various digital health tools such as fitness trackers, meditation apps, and smart scales. While these innovations can greatly enhance our wellness journey, they also raise significant concerns regarding the security of our personal data. Expert...

Continue Reading